2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1617

Autoimmune Diseases in Patients with Cutaneous Lupus Erythematosus
Abstract Number: 1745

Autophagic Memory in Stress Experienced Human T Cells
Abstract Number: 130

Availability of Clinical Measures for Patients with Rheumatoid Arthritis in Integrated Delivery Networks Who Receive a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: A Real-World Analysis of an Electronic Health Records Database
Abstract Number: 1551

Avoidance of Physical Activity Leads to Reduced Inflammatory Enthesitis on Ultrasound
Abstract Number: 33

B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus
Abstract Number: 2974

B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis
Abstract Number: 836

B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation
Abstract Number: 898

B Cell Specific TLR9 Suppresses Disease in Murine Lupus
Abstract Number: 807

B Cells in Giant Cell Arteritis: a Novel Target for Treatment?
Abstract Number: 40

B-Cell Attracting Chemokine-1 (BCA-1) and Macrophage Inflammatory Protein-3 Alpha (MIP-3α) Act Synergistically in the Recruitment of B Cells in the Rheumatoid Synovium
Abstract Number: 2936

B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis
Abstract Number: 35

B-Cell Subset Differences in Inflammatory Rheumatic Diseases
Abstract Number: 56

Baicalein, a Plant-Derived Small Molecule, Activate Nrf2/Autophagy Signaling Axis Via MEK1/2-ERK1/2-Elk1 Pathway to Suppress the Expression of IL-6 in Human Osteoarthritis Chondrocytes
Abstract Number: 415

Baricitinib Reduces GlycA Levels in Phase 2 and Phase 3 Clinical Trials in Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 2316

Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) – a Patient Reported Outcome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].